Immunovant, Inc. (IMVT) News
Filter IMVT News Items
IMVT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IMVT News Highlights
- For IMVT, its 30 day story count is now at 7.
- Over the past 7 days, the trend for IMVT's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- DEC, MG and TOP are the most mentioned tickers in articles about IMVT.
Latest IMVT News From Around the Web
Below are the latest news stories about IMMUNOVANT INC that investors may wish to consider to help them evaluate IMVT as an investment opportunity.
Immunovant (IMVT) Rose on Positive Clinical TrialChartwell Investment Partners, LLC, an affiliate of Carillon Tower Advisers, Inc., released the “Carillon Chartwell Small Cap Value Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here. Information technology and industrials were the top-performing sectors in the Carillon Chartwell Small Cap Growth Fund, with alpha production coming from well-chosen stocks. […] |
Immunovant Scores Much-Needed Win Following Argenx-Led Sell-offImmunovant unveiled promising results for a Graves' disease treatment on Thursday, helping IMVT stock reverse a recent downfall. |
Immunovant (IMVT) Up on Upbeat Initial Batoclimab GD Study DataImmunovant (IMVT) announces positive initial data from the mid-stage study of batoclimab in patients with Graves' disease. The stock gains 12% in the after-market hours, following the news. |
Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of batoclimab in patients with Graves' disease. Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism). The company says the results show that batoclimab meaningfully exceeded 50% response rates. Consistent with studies of batoclimab in other indications, 680 mg administered subcutaneously (SC) in t |
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ DiseaseNEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical trial of batoclimab in patients with Graves’ disease meaningfully exceeded 50% response rates. This Phase 2 proof-of-concept trial is an open-label study to assess the safety and efficacy of batoclimab in Graves |
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ DiseaseNEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical trial of batoclimab in patients with Graves’ disease meaningfully exceeded 50% response rates. This Phase 2 proof-of-concept trial is an open-label study to assess the safety and efficacy of batoclimab in Graves |
11 Stocks Insiders and Billionaires Are Crazy AboutIn this article, we will take a detailed look at the 11 Stocks Insiders and Billionaires Are Crazy About. For a quick overview of such stocks, read our article 5 Stocks Insiders and Billionaires Are Crazy About. In his famous book titled One Up on Wall Street, Peter Lynch talks about how average investors miss out on opportunities by […] |
Here’s Why Immunovant (IMVT) Outperformed in Q3Fred Alger Management, an investment management company, released its “Alger Small Cap Growth Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund outperformed the Russell 2000 Growth Index. The Information Technology and Healthcare sectors contributed to the fund’s relative performance in the quarter, […] |
Immunovant (IMVT) Up on Positive Initial IMVT-1402 MAD Study DataImmunovant (IMVT) posts encouraging initial results from the 600 mg MAD cohort of its early-stage study on IMVT-1402. Stock rises. |
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class PotentialResults from the 600 mg MAD cohort for IMVT-1402 similar to previously disclosed results from the 300 mg MAD cohort for IMVT-1402IMVT-1402 was observed to deliver dose dependent and deep IgG reductions similar to batoclimab in its Phase 1 studyIMVT-1402 600 mg was observed to deliver placebo-like impact on albumin and low-density lipoprotein cholesterol (LDL-C), similar to the previously disclosed 300 mg MAD cohort dataPotential best-in-class profile enables broad and exciting portfolio of indic |